De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Atlas Arteria Beheer

Beheer criteriumcontroles 3/4

De CEO Atlas Arteria's is Graeme Bevans, benoemd in Apr2019, heeft een ambtstermijn van 5.5 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 3.51M, bestaande uit 39.1% salaris en 60.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.05% van de aandelen van het bedrijf, ter waarde A$ 3.48M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 1.8 jaar.

Belangrijke informatie

Graeme Bevans

Algemeen directeur

AU$3.5m

Totale compensatie

Percentage CEO-salaris	39.1%
Dienstverband CEO	5.5yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

Is Now An Opportune Moment To Examine Atlas Arteria Limited (ASX:ALX)?

Apr 07

What Does Atlas Arteria Limited's (ASX:ALX) Share Price Indicate?

Dec 22

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 43% Undervaluation?

Aug 10

Is Atlas Arteria (ASX:ALX) Using Too Much Debt?

May 31

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 48% Undervaluation?

Apr 14

Debra Goodin Is The Independent Chairman of the Board of Atlas Arteria Limited (ASX:ALX) And They Just Picked Up 54% More Shares

Mar 03

Here's Why Atlas Arteria (ASX:ALX) Can Afford Some Debt

Feb 27

Atlas Arteria (ASX:ALX) Has Compensated Shareholders With A Respectable 78% Return On Their Investment

Jan 31

Atlas Arteria Limited (ASX:ALX) Shares Could Be 44% Below Their Intrinsic Value Estimate

Dec 27

How Many Atlas Arteria Limited (ASX:ALX) Shares Do Institutions Own?

Dec 06

Is There Now An Opportunity In Atlas Arteria Limited (ASX:ALX)?

Nov 19

Atlas Arteria (ASX:ALX) Has Gifted Shareholders With A Fantastic 142% Total Return On Their Investment

Jul 30

Analyse CEO-vergoeding

Hoe is Graeme Bevans's beloning veranderd ten opzichte van Atlas Arteria's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	AU$300m
Mar 31 2024	n/a	n/a	AU$312m
Dec 31 2023	AU$4m	AU$1m	AU$324m
Sep 30 2023	n/a	n/a	AU$315m
Jun 30 2023	n/a	n/a	AU$307m
Mar 31 2023	n/a	n/a	AU$287m
Dec 31 2022	AU$4m	AU$1m	AU$267m
Sep 30 2022	n/a	n/a	AU$264m
Jun 30 2022	n/a	n/a	AU$260m
Mar 31 2022	n/a	n/a	AU$222m
Dec 31 2021	AU$3m	AU$1m	AU$183m
Sep 30 2021	n/a	n/a	AU$134m
Jun 30 2021	n/a	n/a	AU$85m
Mar 31 2021	n/a	n/a	AU$13m
Dec 31 2020	AU$2m	AU$1m	-AU$60m
Sep 30 2020	n/a	n/a	-AU$37m
Jun 30 2020	n/a	n/a	-AU$14m
Mar 31 2020	n/a	n/a	AU$2m
Dec 31 2019	AU$3m	AU$1m	AU$17m
Sep 30 2019	n/a	n/a	AU$17m
Jun 30 2019	n/a	n/a	AU$18m
Mar 31 2019	n/a	n/a	AU$47m
Dec 31 2018	AU$2m	AU$696k	AU$77m

Compensatie versus markt: De totale vergoeding ($USD 2.42M ) Graeme } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 2.30M ).

Compensatie versus inkomsten: De vergoeding van Graeme is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Graeme Bevans (66 yo)

5.5yrs

Tenure

AU$3,508,867

Compensatie

Mr. Graeme Francis Bevans serves as Managing Director, Chief Executive Officer and Director at Atlas Arteria Limited since April 1, 2019. Mr. Bevans was a Partner at Alinda Capital Partners LLC since 2010....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Graeme Bevans	MD, CEO & Executive Director	5.5yrs	AU$3.51m	0.050% A$ 3.5m
David Collins	Chief Financial Officer	2.2yrs	AU$1.18m	0.00073% A$ 50.7k
Vincent Portal-Barrault	Chief Operating Officer	5.5yrs	AU$1.59m	0.0079% A$ 551.1k
Hugh Wehby	CEO & MD	less than a year	geen gegevens	geen gegevens
Tess Palmer	Director of Investor Relations	no data	geen gegevens	geen gegevens
Clayton McCormack	Company Secretary & General Counsel	5.5yrs	geen gegevens	geen gegevens
Navleen Prasad	Public Affairs Manager	no data	geen gegevens	geen gegevens
Jim Dickson	Corporate Development & Strategy Executive	no data	geen gegevens	geen gegevens
Catherine Brain	Group Executive of People & Culture	no data	geen gegevens	geen gegevens
Paul Lynch	Joint Company Secretary	3.2yrs	geen gegevens	geen gegevens
Ryan Reynolds	Specialist of Forecasting and Analysis	no data	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van ALX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Graeme Bevans	MD, CEO & Executive Director	5.5yrs	AU$3.51m	0.050% A$ 3.5m
Jean-Georges Malcor	Independent Non-Executive Director	5.9yrs	AU$185.00k	0.0031% A$ 218.2k
David Bartholomew	Independent Non Executive Director	6yrs	AU$185.00k	0.0022% A$ 151.5k
Laura Hendricks	Independent Non-Executive Director	less than a year	AU$39.37k	geen gegevens
Debra Goodin	Independent Non-Executive Chairman	7.1yrs	AU$310.00k	0.0067% A$ 464.9k
Kiernan Bell	Independent Non-executive Director	1.1yrs	geen gegevens	0.00021% A$ 14.6k
Danny Elia	Non-Executive Director	less than a year	geen gegevens	geen gegevens
John Wigglesworth	Independent Non-Executive Director	1.8yrs	AU$185.00k	0.0019% A$ 134.8k
Kenneth Daley	Non-Executive Director	1.4yrs	AU$91.61k	0.00069% A$ 48.0k

1.8yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Atlas Arteria Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Atlas Arteria Limited Appoints Hugh Wehby as Managing Director

Atlas Arteria Limited Announces the Retirement of Graeme Bevans as CEO and Managing Director

Atlas Arteria Limited, Annual General Meeting, May 15, 2024

Atlas Arteria Limited, Annual General Meeting, May 16, 2024

Atlas Arteria Appoints Laura Hendricks to the Board as an Independent Non-Executive Director

Recent updates

First half dividend of AU$0.20 announced

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2024, Payable on 7 October 2024

High number of new directors

Consensus revenue estimates fall by 13%

First half 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Atlas Arteria Limited Appoints Hugh Wehby as Managing Director

Atlas Arteria Limited to Report First Half, 2025 Results on Aug 28, 2025

Final dividend of AU$0.20 announced

Atlas Arteria Limited Announces the Retirement of Graeme Bevans as CEO and Managing Director

Atlas Arteria Limited Announces Distribution for the Six Months Ended 31 December 2023, Payable on 8 April 2024

Atlas Arteria Limited, Annual General Meeting, May 15, 2024

Atlas Arteria Limited, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: AU$0.22 (vs AU$0.25 in FY 2022)

Atlas Arteria Appoints Laura Hendricks to the Board as an Independent Non-Executive Director

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2023, Estimated Payment Date Is 5 October 2023

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2023, Payable on 5 October 2023

Consensus EPS estimates fall by 11%

First half 2023 earnings released: EPS: AU$0.12 (vs AU$0.13 in 1H 2022)

Atlas Arteria Limited Reaffirms Distribution Guidance for the First Half and Second Half of 2023

Atlas Arteria Limited to Report First Half, 2024 Results on Aug 29, 2024

Atlas Arteria Limited Appoints Ken Daley as Director

Atlas Arteria Limited Announces Caroline Foulger Will Retire as A Director, with Effect from 1 July 2023

Consensus EPS estimates fall by 15%

Full year 2022 earnings released: EPS: AU$0.25 (vs AU$0.19 in FY 2021)

Insufficient new directors

Atlas Arteria Limited Announces Board Changes

Atlas Arteria Limited (ASX:ALX) completed the acquisition of 66.67% stake in Skyway Concession Company, LLC from CPP Investments and OMERS Infrastructure.

Now 20% undervalued after recent price drop

Atlas Arteria Limited, Annual General Meeting, Apr 27, 2023

Consensus revenue estimates increase by 10%

Atlas Arteria Limited to Report Q4, 2022 Results on Feb 23, 2023

Price target decreased to AU$6.96

Investor sentiment deteriorated over the past week

Atlas Arteria Limited Provides Distribution Guidance for the Year 2023

Atlas Arteria Limited (ASX:ALX) entered into an agreement to acquire a 66.67% stake in Skyway Concession Company, LLC for $2 billion.

Consensus EPS estimates fall by 14%

First half 2022 earnings released: EPS: AU$0 (vs AU$0.074 in 1H 2021)

Atlas Arteria Limited Provides Dividend Guidance for the First Half of 2022

Price target increased to AU$7.40

Investor sentiment improved over the past week

Atlas Arteria Limited Announces Executive Changes

Is Now An Opportune Moment To Examine Atlas Arteria Limited (ASX:ALX)?

Independent Non-Executive Director recently bought AU$76k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

What Does Atlas Arteria Limited's (ASX:ALX) Share Price Indicate?

Insider recently bought AU$67k worth of stock

First half 2021 earnings released: EPS AU$0.074 (vs AU$0.14 loss in 1H 2020)

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 43% Undervaluation?

Is Atlas Arteria (ASX:ALX) Using Too Much Debt?

Price target decreased to AU$6.21

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 48% Undervaluation?

Debra Goodin Is The Independent Chairman of the Board of Atlas Arteria Limited (ASX:ALX) And They Just Picked Up 54% More Shares

Independent Chairman of the Board recently bought AU$100k worth of stock

Here's Why Atlas Arteria (ASX:ALX) Can Afford Some Debt

Full year 2020 earnings released: AU$0.061 loss per share (vs AU$0.024 profit in FY 2019)

Atlas Arteria Limited Announces Board Changes

New 90-day low: AU$5.97

Atlas Arteria Limited to Report Fiscal Year 2020 Results on Feb 25, 2021

Atlas Arteria (ASX:ALX) Has Compensated Shareholders With A Respectable 78% Return On Their Investment

Atlas Arteria Limited, Annual General Meeting, Apr 27, 2021

Atlas Arteria Limited (ASX:ALX) Shares Could Be 44% Below Their Intrinsic Value Estimate

How Many Atlas Arteria Limited (ASX:ALX) Shares Do Institutions Own?

Is There Now An Opportunity In Atlas Arteria Limited (ASX:ALX)?

Atlas Arteria Limited Announces Changes to its Board

New 90-day low: AU$5.95

New 90-day low: AU$6.07

New 90-day low - AU$6.10

Atlas Arteria Limited (ASX:ALX) acquired 6.14% stake in APRR and ADALEC from Macquarie European Infrastructure Fund II managed by Macquarie Infrastructure and Real Assets (Europe) Limited.